Hikma制药公司削减了指导,并列举了注射方面的挑战,尽管收入增长和新领导层,但导致股份下降17%。 Hikma Pharmaceuticals cut guidance, citing injectables challenges, causing shares to drop 17% despite revenue growth and new leadership.

Hikma制药公司撤出中期指导,预测2026年收入增长2%至4%,低于预期,此后股票下跌17%。 Hikma Pharmaceuticals shares dropped 17% after the company withdrew its medium-term guidance and forecast 2% to 4% revenue growth for 2026, below expectations. 尽管7%的收入增长到33.5亿美元,品牌和Hikma Rx的行业表现强劲,但由于美国的竞争、差价压力和生产延误,其注射业务遇到挑战,导致前景谨慎。 Despite a 7% revenue rise to $3.35 billion and strong performance in branded and Hikma Rx divisions, challenges in its injectables business—due to U.S. competition, margin pressure, and production delays—led to the cautious outlook. 该公司宣布增加5%的红利和2.5亿美元的股票回购,而领导层的变动包括Said Darwazah成为首席执行官和Victoria Hull担任主席。 The company announced a 5% dividend increase and a $250 million share buyback, while leadership changes included Said Darwazah becoming CEO and Victoria Hull as chair. Hikma计划在正在进行的结构调整中增加对可注射研发和制造业的投资。 Hikma plans increased investment in injectables R&D and manufacturing amid ongoing restructuring.